Spots Global Cancer Trial Database for Ascorbate With Durvalumab in Non-Small Cell Lung Cancer (NSCLC)

The following info and data is provided "as is" to help patients around the globe.
We do not endorse or review these studies in any way.

Trial Identification

Brief Title: Ascorbate With Durvalumab in Non-Small Cell Lung Cancer (NSCLC)

Official Title: Assessing the Immunomodulatory Effects of Pharmacologic Ascorbate With Durvalumab (MEDI 4736) in Non-Small Cell Lung Cancer: A Window of Opportunity Trial

Study ID: NCT06083454

Conditions

Non-small Cell Lung Cancer

Interventions

Durvalumab

Pharmacological ascorbate

Surgery (SOC)

Study Description

Brief Summary: This is a descriptive, proof of concept, open-label, randomized, 3-arm, window of opportunity trial to evaluate the immunomodulatory role of pharmacological ascorbate with Durvalumab

Detailed Description: Participants in this research study have stage I Non-Small Cell Lung Cancer (NSCLC) that was found to be suitable for surgery as a first line treatment. The usual treatment for this disease is to remove the tumor with surgery, and then evaluate after surgery if other additional treatments such as chemotherapy or targeted therapy are needed. The purpose of this research study is to compare three different ways of treating stage 1 NSCLC, to see if adding treatment before surgery can reduce the chance of the tumor recurring after surgical removal. In this study, patients will be randomly assigned to one of three treatments: * Durvalumab followed by surgical resection of the tumor. * Durvalumab plus ascorbate (also known as vitamin C), followed by surgical resection of the tumor. * Surgical resection alone. No therapy prior to surgery. This is the same as standard care (SOC) for this disease.